Luis Carlos de Souza Ferreira

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4733394/publications.pdf

Version: 2024-02-01

133 papers	3,849 citations	159358 30 h-index	174990 52 g-index
139 all docs	139 docs citations	139 times ranked	5306 citing authors

#	Article	IF	Citations
1	Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites. International Journal of Biological Sciences, 2022, 18, 15-29.	2.6	5
2	A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates. Vaccine, 2022, 40, 239-246.	1.7	2
3	Nanovaccine based on self-assembling nonstructural protein 1 boosts antibody responses to Zika virus. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 32, 102334.	1.7	7
4	The relationship between cytokine and neutrophil gene network distinguishes SARS-CoV-2â€“infected patients by sex and age. JCI Insight, 2021, 6, .	2.3	17
5	NS1-based ELISA test efficiently detects dengue infections without cross-reactivity with Zika virus. International Journal of Infectious Diseases, 2021, 112, 202-204.	1.5	8
6	Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102445.	1.7	5
7	A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model. OncoImmunology, 2021, 10, 1949896.	2.1	5
8	Intradermal Delivery of Dendritic Cell-Targeting Chimeric mAbs Genetically Fused to Type 2 Dengue Virus Nonstructural Protein 1. Vaccines, 2020, 8, 565.	2.1	1
9	Novel antigenic proteins of Mycoplasma agalactiae as potential vaccine and serodiagnostic candidates. Veterinary Microbiology, 2020, 251, 108866.	0.8	7
10	Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli. Vaccines, 2020, 8, 492.	2.1	18
11	Enhanced Immune Responses and Protective Immunity to Zika Virus Induced by a DNA Vaccine Encoding a Chimeric NS1 Fused With Type 1 Herpes Virus gD Protein. Frontiers in Medical Technology, 2020, 2, 604160.	1.3	2
12	Protective Immunity to Dengue Virus Induced by DNA Vaccines Encoding Nonstructural Proteins in a Lethal Challenge Immunocompetent Mouse Model. Frontiers in Medical Technology, 2020, 2, 558984.	1.3	2
13	Transcutaneous Administration of Dengue Vaccines. Viruses, 2020, 12, 514.	1.5	5
14	A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Molecular Therapy, 2020, 28, 1569-1584.	3.7	188
15	Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors. Molecular Therapy, 2020, 28, 1276-1286.	3.7	29
16	Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization. Vaccine, 2020, 38, 5286-5296.	1.7	5
17	CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. Cell Reports, 2020, 31, 107566.	2.9	31
18	Specificity of NS1-based immunochromatographic tests for dengue virus with regard to the Zika virus protein. International Journal of Infectious Diseases, 2020, 95, 276-278.	1.5	7

#	Article	IF	Citations
19	Optimization and scale-up production of Zika virus Î”NS1 in Escherichia coli: application of Response Surface Methodology. AMB Express, 2020, 10, 1.	1.4	87
20	Strain-specific transcriptional and posttranscriptional regulation of heat-labile toxin expression by enterotoxigenic Escherichia coli. Brazilian Journal of Microbiology, 2020, 51, 455-465.	0.8	3
21	A participaÃ§Ã£o da universidade na produÃ§Ã£o de testes diagnÃ³sticos moleculares do novo coronavÃrus no Brasil: resposta aos desafios sanitÃ¡rios. Cadernos De Saude Publica, 2020, 36, e00115520.	0.4	7
22	Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4+ T Cells to the Dengue Virus Envelope Protein Domain III. Frontiers in Immunology, 2019, 10, 59.	2.2	28
23	Febrile temperatures increase in vitro antibody affinity for malarial and dengue antigens. PLoS Neglected Tropical Diseases, 2019, 13, e0007239.	1.3	13
24	Protein refolding based on high hydrostatic pressure and alkaline pH: Application on a recombinant dengue virus NS1 protein. PLoS ONE, 2019, 14, e0211162.	1.1	17
25	Discordant congenital Zika syndrome twins show differential in vitro viral susceptibility of neural progenitor cells. Nature Communications, 2018, 9, 475.	5.8	86
26	Biosensor-based selective detection of Zika virus specific antibodies in infected individuals. Biosensors and Bioelectronics, 2018, 113, 101-107.	5.3	67
27	Association of high pressure and alkaline condition for solubilization of inclusion bodies and refolding of the NS1 protein from zika virus. BMC Biotechnology, 2018, 18, 78.	1.7	14
28	Persistence and Intra-Host Genetic Evolution of Zika Virus Infection in Symptomatic Adults: A Special View in the Male Reproductive System. Viruses, 2018, 10, 615.	1.5	30
29	Epigenetic regulation of nitric oxide synthase 2, inducible (Nos2) by NLRC4 inflammasomes involves PARP1 cleavage. Scientific Reports, 2017, 7, 41686.	1.6	26
30	Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors. Molecular Cancer Therapeutics, 2017, 16, 1922-1933.	1.9	15
31	In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8+ T cells. Vaccine, 2017, 35, 7240-7249.	1.7	18
32	LT adjuvant modulates epitope specificity and improves the efficacy of murine antibodies elicited by sublingual vaccination with the N-terminal domain of Streptococcus mutans P1. Vaccine, 2017, 35, 7273-7282.	1.7	14
33	Specific Biomarkers Associated With Neurological Complications and Congenital Central Nervous System Abnormalities From Zika Virusâ€“Infected Patients in Brazil. Journal of Infectious Diseases, 2017, 216, 172-181.	1.9	82
34	Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein. Frontiers in Immunology, 2017, 8, 1175.	2.2	27
35	CpG Oligodeoxinucleotides and Flagellin Modulate the Immune Response to Antigens Targeted to CD8Î±+ and CD8Î±â^' Conventional Dendritic Cell Subsets. Frontiers in Immunology, 2017, 8, 1727.	2.2	20
36	Epitope Sequences in Dengue Virus NS1 Protein Identified by Monoclonal Antibodies. Antibodies, 2017, 6, 14.	1.2	19

#	Article	IF	Citations
37	Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen. Vaccine Journal, 2016, 23, 460-469.	3.2	25
38	Protection against HPV-16â€“Associated Tumors Requires the Activation of CD8+ Effector Memory T Cells and the Control of Myeloid-Derived Suppressor Cells. Molecular Cancer Therapeutics, 2016, 15, 1920-1930.	1.9	27
39	A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neuâ€“Expressing Tumor in HLA-A2 Transgenic Mice. Clinical Cancer Research, 2016, 22, 4133-4144.	3.2	19
40	Bacterial spores as particulate carriers for gene gun delivery of plasmid DNA. Journal of Biotechnology, 2016, 228, 58-66.	1.9	18
41	Prolonged Shedding of Zika Virus Associated with Congenital Infection. New England Journal of Medicine, 2016, 375, 1202-1204.	13.9	84
42	Diarrheagenic Escherichia coli. Brazilian Journal of Microbiology, 2016, 47, 3-30.	0.8	337
43	Flagellar Cap Protein FliD Mediates Adherence of Atypical Enteropathogenic Escherichia coli to Enterocyte Microvilli. Infection and Immunity, 2016, 84, 1112-1122.	1.0	12
44	Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model. Virology, 2016, 487, 41-49.	1.1	22
45	Co-administration of plasmid-encoded granulocyte-macrophage colony-stimulating factor increases human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4+ T-cell responses. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 1010-1016.	0.8	10
46	Protective Immunity and Reduced Renal Colonization Induced by Vaccines Containing Recombinant Leptospira interrogans Outer Membrane Proteins and Flagellin Adjuvant. Vaccine Journal, 2015, 22, 965-973.	3.2	30
47	Bacillus subtilis spores as adjuvants for DNA vaccines. Vaccine, 2015, 33, 2328-2334.	1.7	19
48	Modulating APOBEC expression enhances DNA vaccine immunogenicity. Immunology and Cell Biology, 2015, 93, 868-876.	1.0	6
49	Dengue virus models based on mice as experimental hosts. Future Virology, 2015, 10, 835-844.	0.9	2
50	Maternal Vaccination with a Fimbrial Tip Adhesin and Passive Protection of Neonatal Mice against Lethal Human Enterotoxigenic Escherichia coli Challenge. Infection and Immunity, 2015, 83, 4555-4564.	1.0	45
51	Antiâ€metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10. Immunology and Cell Biology, 2015, 93, 86-98.	1.0	24
52	Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. PLoS ONE, 2015, 10, e0138686.	1.1	37
53	Bacillus subtilis Spores as Vaccine Adjuvants: Further Insights into the Mechanisms of Action. PLoS ONE, 2014, 9, e87454.	1.1	41
54	Intradermal Administration of the Type II Heat-Labile Enterotoxins LT-IIb and LT-IIc of Enterotoxigenic Escherichia coli Enhances Humoral and CD8+ T Cell Immunity to a Co-Administered Antigen. PLoS ONE, 2014, 9, e113978.	1.1	12

#	Article	IF	Citations
55	Mucosal vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 2175-2187.	1.4	49
56	The dengue virus non-structural 1 protein: Risks and benefits. Virus Research, 2014, 181, 53-60.	1.1	65
57	Immunogenicity and In Vitro and In Vivo Protective Effects of Antibodies Targeting a Recombinant Form of the Streptococcus mutans P1 Surface Protein. Infection and Immunity, 2014, 82, 4978-4988.	1.0	14
58	Gut Adhesive Bacillus subtilis Spores as a Platform for Mucosal Delivery of Antigens. Infection and Immunity, 2014, 82, 1414-1423.	1.0	47
59	Alzheimer's disease: is a vaccine possible?. Brazilian Journal of Medical and Biological Research, 2014, 47, 438-444.	0.7	11
60	Enhanced Therapeutic Effects Conferred by an Experimental DNA Vaccine Targeting Human Papillomavirus-Induced Tumors. Human Gene Therapy, 2013, 24, 861-870.	1.4	27
61	Cytosolic flagellin-induced lysosomal pathway regulates inflammasome-dependent and -independent macrophage responses. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3321-30.	3.3	50
62	Bacillus subtilis Endospores at High Purity and Recovery Yields: Optimization of Growth Conditions and Purification Method. Current Microbiology, 2013, 66, 279-285.	1.0	47
63	Enterotoxigenic Escherichia coli CS21 pilus contributes to adhesion to intestinal cells and to pathogenesis under in vivo conditions. Microbiology (United Kingdom), 2013, 159, 1725-1735.	0.7	19
64	Bicistronic DNA Vaccines Simultaneously Encoding HIV, HSV and HPV Antigens Promote CD8+ T Cell Responses and Protective Immunity. PLoS ONE, 2013, 8, e71322.	1.1	16
65	Structural and Physiological Analyses of the Alkanesulphonate-Binding Protein (SsuA) of the Citrus Pathogen Xanthomonas citri. PLoS ONE, 2013, 8, e80083.	1.1	13
66	Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine, 2012, 30, 837-845.	1.7	72
67	A Genetic and Pathologic Study of a DENV2 Clinical Isolate Capable of Inducing Encephalitis and Hematological Disturbances in Immunocompetent Mice. PLoS ONE, 2012, 7, e44984.	1.1	23
68	The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide. Frontiers in Microbiology, 2012, 3, 154.	1.5	30
69	Purified Herpes Simplex Type 1 Glycoprotein D (gD) Genetically Fused with the Type 16 Human Papillomavirus E7 Oncoprotein Enhances Antigen-Specific CD8⁺ T Cell Responses and Confers Protective Antitumor Immunity. Molecular Pharmaceutics, 2011, 8, 2320-2330.	2.3	15
70	Functional Diversity of Heat-labile Toxins (LT) Produced by Enterotoxigenic Escherichia coli. Journal of Biological Chemistry, 2011, 286, 5222-5233.	1.6	22
71	Distinctive Immunomodulatory and Inflammatory Properties of the Escherichia coli Type II Heat-Labile Enterotoxin LT-IIa and Its B Pentamer following Intradermal Administration. Vaccine Journal, 2011, 18, 1243-1251.	3.2	12
72	Refolded dengue virus type 2 NS1 protein expressed in Escherichia coli preserves structural and immunological properties of the native protein. Journal of Virological Methods, 2010, 167, 186-192.	1.0	47

#	Article	IF	Citations
73	Induction of neutralizing antibodies in mice immunized with an amino-terminal polypeptide ofStreptococcus mutansP1 protein produced by a recombinantBacillus subtilisstrain. FEMS Immunology and Medical Microbiology, 2010, 59, 131-142.	2.7	11
74	Distribution and biological role of the oligopeptide-binding protein (OppA) in Xanthomonas species. Genetics and Molecular Biology, 2010, 33, 341-347.	0.6	2
75	Biotecnologia aplicada ao desenvolvimento de vacinas. Estudos Avancados, 2010, 24, 19-30.	0.2	8
76	Salmonella enterica Serovar Typhimurium Vaccine Strains Expressing a Nontoxic Shiga-Like Toxin 2 Derivative Induce Partial Protective Immunity to the Toxin Expressed by Enterohemorrhagic Escherichia coli. Vaccine Journal, 2010, 17, 529-536.	3.2	16
77	Immune Responses and Therapeutic Antitumor Effects of an Experimental DNA Vaccine Encoding Human Papillomavirus Type 16 Oncoproteins Genetically Fused to Herpesvirus Glycoprotein D. Vaccine Journal, 2010, 17, 1576-1583.	3.2	27
78	CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine, 2010, 28, 1373-1382.	1.7	45
79	Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella Typhimurium. Vaccine, 2010, 28, 2818-2826.	1.7	38
80	A DNA Vaccine Encoding the Enterohemorragic Escherichia coli Shiga-Like Toxin 2 A 2 and B Subunits Confers Protective Immunity to Shiga Toxin Challenge in the Murine Model. Vaccine Journal, 2009, 16, 712-718.	3.2	33
81	Paracoccidioides brasiliensis Vaccine Formulations Based on the gp43-Derived P10 Sequence and the Salmonella enterica FliC Flagellin. Infection and Immunity, 2009, 77, 1700-1707.	1.0	48
82	Crystallization, data collection and data processing of maltose-binding protein (MalE) from the phytopathogenXanthomonas axonopodispv.citri. Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 105-107.	0.7	1
83	Functional and immunological characterization of a natural polymorphic variant of a heat-labile toxin (LT-I) produced by enterotoxigenicEscherichia coli(ETEC). FEMS Immunology and Medical Microbiology, 2009, 55, 93-99.	2.7	20
84	Crystallographic structure and substrate-binding interactions of the molybdate-binding protein of the phytopathogen Xanthomonas axonopodis pv. citri. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 393-399.	1.1	25
85	Boosting systemic and secreted antibody responses in mice orally immunized with recombinant Bacillus subtilis strains following parenteral priming with a DNA vaccine encoding the enterotoxigenic Escherichia coli (ETEC) CFA/I fimbriae B subunit. Vaccine, 2008, 26, 3998-4005.	1.7	21
86	New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine, 2008, 26, 6132-6142.	1.7	104
87	Expression and Purification of a Recombinant Adenovirus Fiber Knob in a Baculovirus System. Intervirology, 2008, 51, 189-195.	1.2	4
88	Genetic Diversity of Heat-Labile Toxin Expressed by Enterotoxigenic Escherichia coli Strains Isolated from Humans. Journal of Bacteriology, 2008, 190, 2400-2410.	1.0	37
89	Cytotoxic T cell adjuvant effects of three Salmonella enterica flagellins. Brazilian Journal of Microbiology, 2008, 39, 44-49.	0.8	11
90	Evidence of Ball-and-chain Transport of Ferric Enterobactin through FepA. Journal of Biological Chemistry, 2007, 282, 397-406.	1.6	71

#	Article	IF	Citations
91	Evaluation of different promoter sequences and antigen sorting signals on the immunogenicity of Bacillus subtilis vaccine vehicles. Vaccine, 2007, 25, 4671-4680.	1.7	35
92	Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route. Memorias Do Instituto Oswaldo Cruz, 2007, 102, 313-318.	0.8	15
93	The oligopeptide (opp) gene cluster of Streptococcus mutans: identification, prevalence, and characterization. Oral Microbiology and Immunology, 2007, 22, 277-284.	2.8	19
94	Oligopeptide uptake and aminoglycoside resistance in Escherichia coli K12. FEMS Microbiology Letters, 2007, 269, 229-233.	0.7	10
95	Site-directed gene replacement of the phytopathogen Xanthomonas axonopodis pv. citri. Journal of Microbiological Methods, 2006, 65, 171-179.	0.7	9
96	The molybdate-binding protein (ModA) of the plant pathogen Xanthomonas axonopodis pv. citri. Protein Expression and Purification, 2006, 50, 215-222.	0.6	19
97	Stable episomal expression system under control of a stress inducible promoter enhances the immunogenicity of Bacillus subtilis as a vector for antigen delivery. Vaccine, 2006, 24, 2935-2943.	1.7	28
98	Crystallization, data collection and phasing of the molybdate-binding protein of the phytopathogenXanthomonas axonopodispv.citri. Acta Crystallographica Section F: Structural Biology Communications, 2006, 62, 289-291.	0.7	6
99	Clonal relationships among Escherichia coli serogroup O6 isolates based on RAPD. FEMS Microbiology Letters, 2006, 148, 255-260.	0.7	16
100	Production and release of heat-labile toxin by wild-type human-derived enterotoxigenicEscherichia coli. FEMS Immunology and Medical Microbiology, 2006, 48, 123-131.	2.7	25
101	Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors. Anais Da Academia Brasileira De Ciencias, 2005, 77, 113-124.	0.3	50
102	Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes and Infection, 2005, 7, 1541-1550.	1.0	31
103	Construction of plasmid-based expression vectors for Bacillus subtilis exhibiting full structural stability. Plasmid, 2005, 54, 241-248.	0.4	132
104	Purification and in vitro characterization of the maltose-binding protein of the plant pathogen Xanthomonas citri. Protein Expression and Purification, 2005, 43, 103-110.	0.6	17
105	Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli. Vaccine, 2005, 23, 2430-2438.	1.7	17
106	Intracellular polyamine pools, oligopeptide-binding protein A expression, and resistance to aminoglycosides in Escherichia coli. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 789-793.	0.8	6
107	Host and Bacterial Factors Affecting Induction of Immune Responses to Flagellin Expressed by Attenuated Salmonella Vaccine Strains. Infection and Immunity, 2004, 72, 2546-2555.	1.0	32
108	Combined Vaccine Regimen Based on Parenteral Priming with a DNA Vaccine and Administration of an Oral Booster Consisting of a Recombinant Salmonella enterica Serovar Typhimurium Vaccine Strain for Immunization against Infection with Human-Derived Enterotoxigenic Escherichia coli Strains. Infection and Immunity, 2004, 72, 6480-6491.	1.0	18

#	Article	IF	Citations
109	The Oligopeptide Permease (Opp) of the Plant Pathogen Xanthomonas axonopodis pv. citri. Current Microbiology, 2004, 48, 354-359.	1.0	11
110	Genotypic and phenotypic characterization of enterotoxigenicEscherichia coli(ETEC) strains isolated in Rio de Janeiro city, Brazil. FEMS Immunology and Medical Microbiology, 2004, 40, 155-162.	2.7	23
111	Production of recombinant proteins in Escherichia coli. Genetics and Molecular Biology, 2004, 27, 442-453.	0.6	78
112	Beyond Serotypes and Virulence-Associated Factors: Detection of Genetic Diversity among O153:H45 CFA/I Heat-Stable Enterotoxigenic Escherichia coli Strains. Journal of Clinical Microbiology, 2001, 39, 4500-4505.	1.8	15
113	Adjuvant Activity of a Nontoxic Mutant of Escherichia coli Heat-Labile Enterotoxin on Systemic and Mucosal Immune Responses Elicited against a Heterologous Antigen Carried by a Live Salmonella enterica Serovar Typhimurium Vaccine Strain. Infection and Immunity, 2000, 68, 4349-4353.	1.0	31
114	DNA immunisation against the CFA/I fimbriae of enterotoxigenic Escherichia coli (ETEC). Vaccine, 2000, 19, 788-795.	1.7	21
115	Salmonella flagellin fused with a linear epitope of colonization factor antigen I (CFA/I) can prime antibody responses against homologous and heterologous fimbriae of enterotoxigenic Escherichia coli. Research in Microbiology, 2000, 151, 575-582.	1.0	8
116	Antibody responses against flagellin in mice orally immunized with attenuated Salmonella vaccine strains. Archives of Microbiology, 1999, 172, 102-108.	1.0	14
117	Antibody response in mice immunized with a plasmid DNA encoding the colonization factor antigen I of enterotoxigenic Escherichia coli. FEMS Immunology and Medical Microbiology, 1999, 23, 321-330.	2.7	3
118	Phylogenetic affiliation and ultrastructure of uncultured magnetic bacteria with unusually large magnetosomes. Archives of Microbiology, 1998, 169, 136-147.	1.0	127
119	Immunoglobulin G subclass responses in mice immunized with plasmid DNA encoding the CFA/I fimbria of enterotoxigenic Escherichia coli. Immunology Letters, 1998, 62, 145-149.	1.1	15
120	Epitope specificity of antibodies raised against enterotoxigenic Escherichia coli CFA/I fimbriae in mice immunized with naked DNA. Vaccine, 1998, 16, 9-15.	1.7	20
121	OppA Escherichia coli mutants have osmodependent resistance to aminoglycoside antibiotics. Genetics and Molecular Biology, 1998, 21, 15-19.	0.6	1
122	Cloning and expression of colonization factor antigen I (CFA/I) epitopes of enterotoxigenic Escherichia coli (ETEC) in Salmonella flagellin. Research in Microbiology, 1997, 148, 217-228.	1.0	22
123	Detection of Penicillin-binding Proteins in the Endosymbiont of the Trypanosomatid Crithidia deanei. Journal of Eukaryotic Microbiology, 1997, 44, 492-496.	0.8	21
124	Characterization of enterotoxigenic Escherichia coli by random amplification of polymorphic DNA. Research in Microbiology, 1996, 147, 175-182.	1.0	34
125	Relationship between outer membrane protein and lipopolysaccharide profiles and serotypes of enterotoxigenic Escherichia coli isolated in Brazil. FEMS Microbiology Letters, 1996, 143, 253-258.	0.7	21
126	Effect of sigma factor S (sigmaS) on the stability of penicillin-binding protein 3 (PBP3) of Escherichia colt K12. Genetics and Molecular Biology, 1996, 19, 545-549.	1.0	0

#	Article	IF	Citations
127	Surface-Exposed Antigenic Determinants in Outer Membranes of Wild Yersinia pestis Isolates. Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology, 1991, 276, 73-85.	0.5	0
128	Screening the mutagenic activities of coomonly used antiparasite drugs by the Simultest, a simplified Salmonella/microsome plate incorporation assay. Revista Do Instituto De Medicina Tropical De Sao Paulo, 1990, 32, 269-274.	0.5	16
129	Plasmid composition and virulence-associated factors of Yersinia pestis isolates from a plague outbreak at the ParaÃba State, Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 1989, 31, 295-300.	0.5	10
130	Electrophoretic characterisation of the outer membrane proteins ofYersinia pestisisolated in north-east Brazil. Epidemiology and Infection, 1989, 103, 595-602.	1.0	6
131	Properties and crystallization of a genetically engineered, water-soluble derivative of penicillin-binding protein 5 of Escherichia coli K12. FEBS Journal, 1988, 171, 11-16.	0.2	34
132	Activation of anti-Trypanosoma cruzi drugs to genotoxic metabolites promoted by mammalian microsomal enzymes. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1988, 204, 577-583.	1.2	15
133	Mutagenicity of CL 64 855, a potent anti-Trypanosoma cruzi drug. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1986, 171, 11-15.	1.2	20